Ant International’s WorldFirst Accelerates SEA Growth with Malaysia MSB Licence
Ant International has obtained approval from Bank Negara Malaysia to carry out business under a Class A Money Services Business licence. The licence will empower Ant International’s WorldFirst—an all-in-one digital cross-border payment and treasury account service for global businesses—to operate in Malaysia, adding to its 60+ global licences worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806541491/en/
WorldFirst's All-in-One Business Account for Global Payments
The licence will enable WorldFirst to expand its product offerings and roll out new services in Malaysia, facilitating international payments, especially in receiving foreign currency payments globally, with a focus on supporting small and medium-sized enterprises (SMEs) to manage their cross-border transactions more efficiently. It further strengthens WorldFirst’s capabilities in supporting businesses expanding both into and out of the Malaysian market.
The Going-Global: Seizing the Next Great Opportunity in Digital Trade report (Deloitte & WorldFirst) identifies Malaysia as a High-Potential Market with strong digital trade growth. The country's digital economy is now a key growth driver, with e-commerce GMV projected to reach $16 billion by 2025 and $25 billion by 2030.
The rapid digitalisation is fuelling demand for innovative financial services across Southeast Asia, with Malaysia emerging as a regional leader. WorldFirst finds Malaysian merchants more actively seeking multi-currency solutions and adopting more diverse payment methods than regional peers. They prioritise these key factors: faster transaction settlement, competitive FX rates with hedging solutions and diversified financial product offerings.
Recognising the specific demands of Malaysian merchants, WorldFirst aims to deliver tailored solutions featuring global coverage, secure transactions and operational efficiency—essential foundations for Malaysian SMEs’ success in today's digital economy.
Central to this offering is the World Account, WorldFirst's flagship product that combines global payments, collections, FX conversion, and treasury management in one single account. Sellers can effortlessly collect from 130+ marketplaces (including Amazon, Walmart, etc.), while buyers can gain easy payment solutions for international sourcing.
WorldFirst has also established localised operations in Malaysia to provide tailored support for SMEs pursuing global expansion. This move aligns with its parent company Ant International's strategic investment in the country, including the launch of a Digital Business Centre focused on harnessing local tech talent to drive global innovation.
“The licence marks a significant milestone in WorldFirst's commitment to Southeast Asia. More importantly, it enables us to better serve Southeast Asian SMEs with secure, compliant cross-border financial services while contributing to the region's digital ecosystem,” said Clara Shi, Vice President of Ant International and CEO of WorldFirst.
In 2025, WorldFirst leverages its experience serving over 1.2 million SMEs worldwide through products like the newly launched World Card with Mastercard. Currently available in other markets, the World Card provides the ease, security, and international reach SMEs need to scale globally while managing spending efficiently.
About WorldFirst
WorldFirst offers cross-border payments and treasury services through its global business account, empowering growth for SMEs in e-commerce, trade, and the broad platform economy. WorldFirst simplifies key financial operations, including international payments, collections, currency conversions, and treasury management, all in a one-stop account. Leveraging the technological strengths of its parent company Ant International, WorldFirst delivers industry-leading transaction security and reliability. WorldFirst has supported over 1.2 million customers, enabling payments in 100+ currencies across more than 210 countries and regions. Learn more about WorldFirst at https://www.worldfirst.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250806541491/en/
Contacts
Chloe Zhu
jingchong.zhu@ant-intl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
k-ID Strengthens Leadership Team with Former Xbox Family Product Lead Mike Mongeau1.9.2025 10:00:00 EEST | Press release
k-ID, the global compliance platform transforming age-appropriate digital experiences for young people worldwide, today announced the appointment of Mike Mongeau as Head of Product. Mongeau joins k-ID from Microsoft, where he spearheaded Xbox’s family gaming experience, ensuring millions of kids could game safely while giving parents the tools to feel confident about their play. Mongeau will leverage his extensive experience in youth safety technology and product development to advance k-ID's mission of creating trusted, age-appropriate digital experiences for kids and teens globally. His appointment comes as k-ID rapidly expands its partnerships with leading publishers and platforms, such as Discord, Hasbro, Nexus Mods, and GorillaTag. "Mike brings an invaluable combination of deep technical expertise in family safety and a genuine passion for empowering young people in digital spaces," said Kieran Donovan, CEO and Co-Founder of k-ID. "His track record at Xbox demonstrates exactly the
CapVest to Acquire Majority Stake in STADA from Bain Capital and Cinven1.9.2025 09:49:00 EEST | Press release
CapVest Partners LLP (“CapVest”), a leading global investment firm, has today signed a definitive agreement with Bain Capital and Cinven to acquire the majority stake in STADA Arzneimittel AG “(STADA” or “the Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty pharmaceuticals. Headquartered in Bad Vilbel, Germany, STADA is a leading European pharmaceutical company focused on three strategic pillars: Consumer Healthcare, Generics and Specialty Pharmaceuticals. The company was acquired by Bain Capital and Cinven in 2017. Working with management, the two international investment firms helped transform the company from a traditional German generics business into a leading, diversified global healthcare platform with a strategic focus on Consumer Healthcare, Generics and Specialty Pharmaceuticals. During this period, STADA grew into a multifaceted, resilient company, generating revenues in excess of €4 billion, delivering a
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom